RELMADA THERAPEUTICS, INC. Program Rights Obligations, Noncurrent
RELMADA THERAPEUTICS, INC. (RLMD) had Program Rights Obligations, Noncurrent of $5.08 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:ProgramRightsObligationsNoncurrent · last filed 2026-08-06
- 2026-06-30: Program Rights Obligations, Noncurrent $5.08M.
- 2026-03-31: Program Rights Obligations, Noncurrent $3.74M.
- 2025-12-31: Program Rights Obligations, Noncurrent $1.06M.
- 2025-09-30: Program Rights Obligations, Noncurrent $221.11K.
| Period end | Program Rights Obligations, Noncurrent |
|---|---|
| 2026-06-30 | $5.08M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.74M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.06M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $221.11K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $32.12K 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.50K 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.47K 10-K · filed 2026-03-19 |
| 2024-09-30 | $12.56K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |